Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Income from Continuing Operations readings, the most recent being 63734000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 12.33% to 63734000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 214558000.0, a 14.19% increase, with the full-year FY2025 number at 207561000.0, up 34.4% from a year prior.
  • Income from Continuing Operations hit 63734000.0 in Q1 2026 for Catalyst Pharmaceuticals, up from 45933000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 63734000.0 in Q1 2026 to a low of 30764000.0 in Q3 2023.
  • Median Income from Continuing Operations over the past 5 years was 37762000.0 (2023), compared with a mean of 33599823.53.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 267.96% in 2022 and later tumbled 235.24% in 2023.
  • Catalyst Pharmaceuticals' Income from Continuing Operations stood at 34253000.0 in 2022, then tumbled by 50.26% to 17039000.0 in 2023, then soared by 172.8% to 46483000.0 in 2024, then decreased by 1.18% to 45933000.0 in 2025, then surged by 38.75% to 63734000.0 in 2026.
  • The last three reported values for Income from Continuing Operations were 63734000.0 (Q1 2026), 45933000.0 (Q4 2025), and 52783000.0 (Q3 2025) per Business Quant data.